EUVIMEDEUVIMED entdecken
Kommentar

Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?

Kristina Jenei, Bishal Gyawali

HealthcarePapers · 2023

DOI: 10.12927/hcpap.2023.26996 ↗

Kurz gefasst

Kommentar in der Zeitschrift HealthcarePapers, 2023. Verfasst von Kristina Jenei und 1 weiteren Autor:innen. Beteiligte Einrichtung: Research Associate, School of Population and Public Health, University of British Columbia, Vancouver, BC. Hauptthemen laut MEDLINE: Rare Diseases, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer medicines comprise the largest proportion of expensive drugs for rare diseases (EDRDs). The US Orphan Drug Act (ODA) (Office of Inspector General, Department of Health and Human Services 2001) encourages pharmaceutical manufacturers to develop medicines for rare diseases through a range of financial incentives, which has shifted the development of cancer medicines to rare cancer subtypes. Although certain medicines approved through the ODA have revolutionized cancer treatment, only half demonstrate added therapeutic benefit compared to existing alternatives. Canadian regulators should ensure that cancer medicines that receive fast-track approval through the Health Canada Notice of Compliance with conditions offer benefit to Canadian patients. Furthermore, payers might engage in methods for reassessment and renegotiations over the medicines' lifespan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rare DiseasesNeoplasmsHumansDrug ApprovalCanadaOrphan Drug ProductionMotivation

Autor:innen und Institutionen

  • Research Associate, School of Population and Public Health, University of British Columbia, Vancouver, BC.
  • Associate Professor, Oncology and Public Health Sciences, Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, ON.

Zitieren

APA

Jenei, K., & Gyawali, B. (2023). Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?. HealthcarePapers. https://doi.org/10.12927/hcpap.2023.26996

Vancouver

Jenei K, Gyawali B. Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?. HealthcarePapers. 2023. doi:10.12927/hcpap.2023.26996

BibTeX
@article{Jenei2023,
  author = {Jenei, Kristina and Gyawali, Bishal},
  title = {Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?},
  journal = {HealthcarePapers},
  year = {2023},
  doi = {10.12927/hcpap.2023.26996}
}
Kostenlos starten →